As markets struggle, keen BioMed investors will keep making money

The good news is that while most of the market is flat, there is still lots of volatility and action to be had in the healthcare sector.  These stocks move! Most other sectors are stagnant. Watching the movement in their stock prices is about as exciting as watching paint dry.

The biomedical sector shows great resolve as the rest of the market falls apart and as the big pharmaceutical giants' pipelines dry up, that only makes things for the small caps and upstarts far more intriguing. There will be many fortunes made by investors and traders who recognize this and can act both astutely and sensibly.

As I said yesterday, the biggest trades in the biotech sector have happened for us after digging for good intelligence. That means having up to date, reliable information about not only good up-and-coming companies, but also arming up with knowledge of important catalyst events- like upcoming FDA decisions and approvals- which undoubtedly have an impact on the prices of bio company shares. Look at the big boys here for guidance. Institutional investors pay big bucks (tens of thousands of dollars per year) for information like that. Until now, the vast majority of institutional investors had no way to access that information. As a news and information portal, we're actively attempting to change that. Soon, you'll see even more tools and information that will help lead the way.

Things may be about to get even more interesting for the over all market, but if you're going to actively trade  and invest in biotech stocks during this uncertain time you need to be smart and in order to be truly smart, you first need to be informed.

Let's talk about  a couple of small-cap companies I continue to keep an eye on based on the recent trading volume and chatter.

First, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).  Even though the company was asked to provide more information to the FDA regarding their application for Zevalin as an initial treatment for non-Hodgkin's lymphoma, credible industry observers believe that the company should be feeling confident that the data it will submit will satisfy the  the Complete Response letter's requirements. In addition, they feel that after seeing this type of scenario play out many times before, SPPI should expect a favorable regulatory decision. The drug is already approved as a treatment for non-Hodgkin's lymphoma patients who have relapsed. An approval would mean tremendous new revenue opportunities. In addition, the company has a second pending decision for approval by the FDA this October and that is very rare.

Second, penny play BioElectronics Corporation (OTC:BIEL), rose a couple of cents since I told you about it. Look for it to continue to attract attention. The technology they use actually has it's roots in the work of Nikola Tesla, who is best known for many revolutionary contributions in the field of electricty and magnetism.  It not only relieves pain, it also appears to show some healing propeties at the cellular level. Sounds like sci-fi, but studies apparently back up the claims. I'm in the process of tracking down a company spokesman and will try to dig for more information about the technology and this small company's future plans.  The headline grabbing concerns posed by the FDA about possible restrictions of common painkillers and theliver damage they cause, this small bio play could continue upwards. Look for them to continue to put out their own good news as well.

Here's a look at the last session's movers and shakers:

Disclosure: No positions

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

---

Add this page to your favorite Social Bookmarking websites